N/A
Manufactured by Pfizer Laboratories Div Pfizer Inc
142,758 FDA adverse event reports analyzed
Last updated: 2026-04-14
INFLIXIMAB DYYB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Pfizer Laboratories Div Pfizer Inc. The most commonly reported adverse reactions for INFLIXIMAB DYYB include OFF LABEL USE, CONDITION AGGRAVATED, INTENTIONAL PRODUCT USE ISSUE, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION, ARTHRALGIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for INFLIXIMAB DYYB.
Out of 27,627 classified reports for INFLIXIMAB DYYB:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 142,758 FDA FAERS reports that mention INFLIXIMAB DYYB. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, CONDITION AGGRAVATED, INTENTIONAL PRODUCT USE ISSUE, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION, ARTHRALGIA, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Pfizer Laboratories Div Pfizer Inc in connection with INFLIXIMAB DYYB. Always verify the specific product and NDC with your pharmacist.